[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-001", "question": "A 16-year-old female presents with episodes of muscle weakness and palpitations. Physical exam reveals low-set ears, micrognathia, and clinodactyly. ECG demonstrates frequent PVCs, a QTc of 490 ms, and prominent U waves. Genetic testing confirms a loss-of-function mutation in KCNJ2. She continues to have frequent non-sustained ventricular tachycardia despite beta-blocker therapy. What is the most appropriate pharmacologic management for her arrhythmia?", "options": ["Option A: Nadolol", "Option B: Amiodarone", "Option C: Flecainide", "Option D: Mexiletine", "Option E: Verapamil"], "answer": "C", "answer_index": 2, "explanation": "This patient has Andersen-Tawil Syndrome (LQT7), characterized by the triad of periodic paralysis, dysmorphic features, and QT/U wave abnormalities. Unlike other Long QT Syndromes where sodium channel blockers are often contraindicated, Flecainide is uniquely effective in suppressing the ventricular arrhythmias associated with KCNJ2 mutations.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptoms and physical findings suggestive of Andersen-Tawil syndrome (ATS), which is caused by mutations in the KCNJ2 gene, encoding the Kir2.1 potassium channel. This syndrome is characterized by a triad of periodic paralysis, cardiac arrhythmias (including prolonged QTc and ventricular arrhythmias), and dysmorphic features. The ECG findings of a prolonged QTc (490 ms) and prominent U waves are consistent with ATS. The presence of frequent PVCs and non-sustained ventricular tachycardia despite beta-blocker therapy indicates a refractory arrhythmia.\n\nLet's analyze the options:\n\nA. Nadolol: Nadolol is a non-selective beta-blocker. While beta-blockers are often a first-line treatment for arrhythmias in ATS, the patient is already on beta-blocker therapy and continues to have frequent ventricular tachycardia, suggesting it's not sufficient.\n\nB. Amiodarone: Amiodarone is a Class III antiarrhythmic agent that prolongs the action potential duration and effective refractory period. It is effective in treating ventricular arrhythmias, including those seen in ATS. Given the failure of beta-blockers, amiodarone is a strong consideration for refractory ventricular arrhythmias.\n\nC. Flecainide: Flecainide is a Class Ic antiarrhythmic agent. While it can be used for supraventricular arrhythmias, it is generally contraindicated in patients with structural heart disease or significant ventricular arrhythmias due to its proarrhythmic potential. In ATS, the underlying channelopathy can predispose to arrhythmias, and flecainide might not be the safest choice.\n\nD. Mexiletine: Mexiletine is a Class Ib antiarrhythmic agent. It is primarily used for ventricular arrhythmias in the setting of myocardial infarction. Its efficacy in ATS is not well-established, and it might not be the most appropriate choice for this specific channelopathy.\n\nE. Verapamil: Verapamil is a Class IV antiarrhythmic agent (calcium channel blocker). While calcium channel blockers can be used in some cardiac conditions, they are not typically the primary treatment for the ventricular arrhythmias seen in ATS, especially when beta-blockers have failed. In fact, some studies suggest that calcium channel blockers might worsen periodic paralysis in ATS.\n\nConsidering the refractory ventricular arrhythmias in a patient with confirmed KCNJ2 mutation (Andersen-Tawil syndrome) despite beta-blocker therapy, amiodarone is the most appropriate pharmacologic management among the given options due to its broad efficacy against ventricular arrhythmias and its established role in managing complex cardiac channelopathies.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-002", "question": "A 55-year-old man presents with bone pain and exophthalmos. CT imaging reveals perinephric infiltration with a 'hairy kidney' appearance and osteosclerotic lesions in the distal femur. Biopsy of the retroperitoneal tissue shows infiltration by foamy histiocytes that are CD68+ and CD1a-. Molecular testing reveals a BRAF V600E mutation. Which therapeutic agent is most indicated?", "options": ["Option A: Rituximab", "Option B: High-dose Prednisone", "Option C: Vemurafenib", "Option D: Methotrexate", "Option E: Infliximab"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation (hairy kidney, osteosclerosis, exophthalmos) and pathology (CD68+, CD1a- foamy histiocytes) are diagnostic of Erdheim-Chester Disease (ECD), a non-Langerhans cell histiocytosis. Over 50% of cases carry the BRAF V600E mutation. Targeted therapy with a BRAF inhibitor (Vemurafenib) is the treatment of choice for BRAF-positive ECD, superior to empiric immunosuppression.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with a constellation of findings suggestive of Erdheim-Chester disease (ECD) with a specific molecular abnormality. Let's break down the clues:\n\n*   **Bone pain and exophthalmos:** These are common manifestations of ECD.\n*   **Perinephric infiltration with a 'hairy kidney' appearance:** This is a classic CT finding in ECD.\n*   **Osteosclerotic lesions in the distal femur:** Another characteristic skeletal finding in ECD.\n*   **Biopsy showing foamy histiocytes that are CD68+ and CD1a-:** This is consistent with the histopathology of ECD, which involves the accumulation of lipid-laden histiocytes. CD1a negativity helps differentiate it from Langerhans cell histiocytosis.\n*   **BRAF V600E mutation:** This is a crucial piece of information. The BRAF V600E mutation is found in a significant proportion of ECD patients and is a targetable mutation.\n\nNow let's consider the treatment options in the context of ECD and the BRAF V600E mutation:\n\n*   **A. Rituximab:** While rituximab can be used in some histiocytic disorders, it's not the primary targeted therapy for BRAF V600E-mutated ECD.\n*   **B. High-dose Prednisone:** Corticosteroids can be used for symptomatic management in some histiocytic disorders, but they are not a targeted therapy for the underlying molecular defect in BRAF V600E-mutated ECD.\n*   **C. Vemurafenib:** Vemurafenib is a BRAF inhibitor specifically designed to target the BRAF V600E mutation. Given the presence of this mutation in the patient's retroperitoneal tissue, vemurafenib is a highly indicated therapeutic agent.\n*   **D. Methotrexate:** Methotrexate is an immunosuppressant and chemotherapy agent. It is not a targeted therapy for BRAF V600E-mutated ECD.\n*   **E. Infliximab:** Infliximab is a TNF-alpha inhibitor. While inflammation plays a role in ECD, it's not the primary targeted therapy for the BRAF V600E mutation.\n\nTherefore, the presence of the BRAF V600E mutation makes vemurafenib the most indicated therapeutic agent.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-003", "question": "A 32-year-old G1P0 woman at 35 weeks gestation presents with nausea, vomiting, and jaundice. Labs show AST 300 U/L, ALT 350 U/L, Platelets 80,000/mm3, Glucose 45 mg/dL, and INR 2.5. A diagnosis of Acute Fatty Liver of Pregnancy (AFLP) is made, and the infant is delivered urgently. To prevent sudden death in the neonate, which specific screening test should be prioritized?", "options": ["Option A: Serum ammonia and lactate", "Option B: Plasma acylcarnitine profile", "Option C: Galactose-1-phosphate uridyltransferase", "Option D: Very long-chain fatty acids (VLCFA)", "Option E: Hemoglobin electrophoresis"], "answer": "B", "answer_index": 1, "explanation": "Maternal AFLP is strongly associated with fetal Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Fetal fatty acid oxidation defects cause accumulation of metabolites that cross the placenta and overwhelm the maternal liver. The neonate is at high risk for hypoketotic hypoglycemia and sudden death; an acylcarnitine profile is diagnostic.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The question describes a neonate born to a mother with Acute Fatty Liver of Pregnancy (AFLP). AFLP is a rare but serious complication of pregnancy that can lead to liver failure in both the mother and the fetus. Neonates born to mothers with AFLP are at increased risk for certain metabolic disorders, particularly those affecting fatty acid oxidation.\n\nLet's analyze the options:\n\nA. Serum ammonia and lactate: Elevated ammonia and lactate can indicate various metabolic disorders, including urea cycle defects and mitochondrial disorders. While these can be serious, they are not the *most specific* screening test for the primary concern related to AFLP in the neonate.\n\nB. Plasma acylcarnitine profile: This test is a cornerstone for screening for inborn errors of metabolism, particularly those affecting fatty acid oxidation (e.g., medium-chain acyl-CoA dehydrogenase deficiency - MCADD). Neonates born to mothers with AFLP have an increased risk of fatty acid oxidation disorders due to the metabolic stress and potential for impaired maternal-fetal nutrient transfer. These disorders can present with hypoglycemia, liver dysfunction, and neurological symptoms, which can be life-threatening if not identified and managed promptly.\n\nC. Galactose-1-phosphate uridyltransferase: This enzyme is deficient in galactosemia, a disorder of carbohydrate metabolism. While important to screen for, it is not the most directly related to the risks associated with AFLP.\n\nD. Very long-chain fatty acids (VLCFA): Elevated VLCFAs are characteristic of X-linked adrenoleukodystrophy (X-ALD), a peroxisomal disorder. While a serious condition, it's not the primary metabolic concern directly linked to the pathophysiology of AFLP in the neonate.\n\nE. Hemoglobin electrophoresis: This test is used to screen for hemoglobinopathies like sickle cell disease and thalassemia. These are genetic blood disorders and are not directly related to the metabolic consequences of AFLP.\n\nGiven the context of AFLP and the risk of metabolic complications related to fatty acid metabolism in the neonate, a plasma acylcarnitine profile is the most appropriate and specific screening test to prioritize for preventing sudden death.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-004", "question": "A 24-year-old male with HIV and known G6PD deficiency develops cyanosis and dyspnea after receiving dapsone. SpO2 is 85% and arterial blood is chocolate-colored. Methemoglobin level is 25%. He is inadvertently treated with methylene blue, after which his condition deteriorates with evidence of acute hemolysis and worsening hypoxia. What is the most appropriate next step in management?", "options": ["Option A: Repeat Methylene Blue dose", "Option B: High-dose Ascorbic Acid (Vitamin C)", "Option C: Exchange transfusion", "Option D: Hyperbaric oxygen therapy", "Option E: Hydroxocobalamin"], "answer": "C", "answer_index": 2, "explanation": "Methylene blue requires NADPH (generated via the G6PD pathway) to reduce methemoglobin. In G6PD deficiency, it is ineffective and can induce severe hemolysis (as seen here). Ascorbic acid is too slow for acute severe toxicity. Exchange transfusion is the definitive rescue therapy to rapidly remove the methemoglobin and the offending agent.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has methemoglobinemia, likely exacerbated by dapsone in the setting of G6PD deficiency. Methylene blue is a standard treatment for methemoglobinemia, but it can paradoxically worsen hemolysis in G6PD-deficient individuals. The patient's deterioration after methylene blue, with evidence of acute hemolysis and worsening hypoxia, suggests this is the case.\n\nLet's analyze the options:\n\nA. Repeat Methylene Blue dose: This is contraindicated given the patient's deterioration after the initial dose and known G6PD deficiency.\n\nB. High-dose Ascorbic Acid (Vitamin C): Ascorbic acid is a reducing agent that can help convert methemoglobin back to hemoglobin. It is often used as an adjunct or alternative treatment for methemoglobinemia, especially when methylene blue is contraindicated or ineffective. It can also have a protective effect against hemolysis.\n\nC. Exchange transfusion: This is a drastic measure and typically reserved for severe cases of methemoglobinemia or hemolysis that are unresponsive to other treatments. While the patient is hypoxic, the primary issue appears to be methemoglobinemia and hemolysis, and other less invasive options should be considered first.\n\nD. Hyperbaric oxygen therapy: Hyperbaric oxygen therapy is not a standard treatment for methemoglobinemia. While it increases oxygen delivery, it doesn't directly address the methemoglobin itself.\n\nE. Hydroxocobalamin: Hydroxocobalamin is another antidote for cyanide poisoning and can also be used for methemoglobinemia. It works by binding to methemoglobin and converting it back to hemoglobin. It is generally well-tolerated and does not cause hemolysis in G6PD-deficient individuals. However, ascorbic acid is a more readily available and commonly used option in this scenario, especially given the potential for hemolysis.\n\nConsidering the patient's G6PD deficiency and the adverse reaction to methylene blue, ascorbic acid is the most appropriate next step. It can help reduce methemoglobin and potentially mitigate hemolysis.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-005", "question": "A 3-month-old male presents with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic diarrhea. CBC reveals eosinophilia and lymphocytosis. Immunophenotyping shows an absence of B cells, but elevated numbers of oligoclonal, activated T cells. Which genetic defect is most consistent with this presentation?", "options": ["Option A: BTK mutation", "Option B: Hypomorphic RAG1/RAG2 mutation", "Option C: CD40 Ligand mutation", "Option D: STAT3 mutation", "Option E: WAS gene mutation"], "answer": "B", "answer_index": 1, "explanation": "This is Omenn Syndrome, a form of 'leaky' Severe Combined Immunodeficiency (SCID). It is caused by hypomorphic mutations in RAG1 or RAG2 that allow for partial V(D)J recombination. This results in the absence of B cells but the development of a restricted, autoreactive T-cell repertoire that infiltrates tissues (erythroderma, hepatosplenomegaly) and causes high IgE/eosinophilia.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a constellation of symptoms suggestive of a severe combined immunodeficiency (SCID) or a related disorder. Let's analyze the findings:\n\n*   **Generalized erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic diarrhea:** These are non-specific but can be seen in various immune deficiencies, including SCID. Erythroderma can be a sign of T-cell activation or a cutaneous manifestation of immune dysregulation.\n*   **Eosinophilia and lymphocytosis:** Eosinophilia can be seen in certain immune deficiencies, particularly those involving T-cell dysregulation or parasitic infections (though the latter is less likely to be the primary cause here). Lymphocytosis, especially with activated T cells, is a key finding.\n*   **Absence of B cells:** This is a hallmark of SCID, indicating a defect in B-cell development.\n*   **Elevated numbers of oligoclonal, activated T cells:** This is a critical clue. The presence of T cells, even if oligoclonal and activated, suggests that the defect might not be a complete absence of T-cell development (as in some forms of SCID) but rather a problem with T-cell function or regulation, or a defect that allows some T-cell development but impairs B-cell development. Oligoclonality suggests a limited repertoire of T-cell expansion, possibly in response to persistent antigens or due to intrinsic T-cell abnormalities.\n\nNow let's consider the options:\n\n*   **A. BTK mutation:** Bruton's tyrosine kinase (BTK) is essential for B-cell development and function. A BTK mutation causes X-linked agammaglobulinemia (XLA), characterized by absent B cells and low immunoglobulins. However, T-cell numbers and function are typically normal. This patient has lymphocytosis with activated T cells, which is not typical of XLA.\n*   **B. Hypomorphic RAG1/RAG2 mutation:** Mutations in RAG1 or RAG2 lead to SCID. Hypomorphic mutations can result in a leaky SCID, where some T and B cells develop but are dysfunctional. This can lead to a spectrum of presentations, including severe immune deficiency. However, the presence of *elevated* numbers of *activated* T cells and *absence* of B cells is more specific. While RAG deficiency can lead to absent B cells, the T-cell picture might not always be this specific.\n*   **C. CD40 Ligand mutation:** CD40 ligand (CD40L) is crucial for T-cell help to B cells, leading to B-cell maturation and immunoglobulin class switching. A CD40L mutation causes X-linked hyper-IgM syndrome. Patients typically have normal or elevated B-cell numbers but a defect in antibody production and class switching. They also have impaired T-cell dependent immune responses. This patient has an *absence* of B cells, which is not characteristic of hyper-IgM syndrome.\n*   **D. STAT3 mutation:** Signal transducer and activator of transcription 3 (STAT3) plays a critical role in the signaling pathways of many cytokines, including IL-10 and IL-21, which are important for T-cell differentiation, B-cell function, and immune regulation. Autosomal dominant or recessive STAT3 mutations can cause a spectrum of disorders, including Hyper-IgE syndrome (HIES) and a SCID-like phenotype. A key feature of STAT3 deficiency is impaired T-cell function and differentiation, often leading to lymphadenopathy, recurrent infections, and sometimes eczema-like rashes. Importantly, STAT3 mutations can lead to a severe combined immunodeficiency-like presentation with absent or severely reduced B cells, and a skewed T-cell population, including oligoclonal T cells. The elevated numbers of activated T cells and absence of B cells, along with the other symptoms, are highly consistent with a STAT3 mutation.\n*   **E. WAS gene mutation:** The Wiskott-Aldrich syndrome (WAS) protein is involved in cytoskeletal regulation and is important for T-cell and B-cell function, as well as platelet function. WAS is characterized by eczema, thrombocytopenia (small platelets), and recurrent infections. While immune dysregulation is present, the absence of B cells is not a primary feature, and the T-cell picture is usually different.\n\nConsidering the combination of absent B cells, lymphocytosis with oligoclonal, activated T cells, and the other clinical features, a STAT3 mutation is the most consistent genetic defect. STAT3 deficiency can lead to a severe impairment of B-cell development while allowing for some T-cell activation and proliferation, often in an oligoclonal manner.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-006", "question": "A 4-month-old infant presents with failure to thrive and diaphoresis during feeding. ECG reveals deep Q waves in leads I, aVL, and V5-V6. Echocardiography demonstrates a dilated left ventricle. During color Doppler interrogation of the coronary arteries, which flow pattern confirms the diagnosis of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA)?", "options": ["Option A: Diastolic flow from the aorta into the left coronary artery", "Option B: Systolic flow from the pulmonary artery into the left coronary artery", "Option C: Retrograde flow from the left coronary artery into the pulmonary artery", "Option D: Continuous flow from the aorta to the pulmonary artery", "Option E: Turbulent high-velocity flow at the left coronary ostium"], "answer": "C", "answer_index": 2, "explanation": "In the infant/adult type of ALCAPA, pulmonary vascular resistance drops, causing flow reversal. Blood flows from the aorta to the Right Coronary Artery, through collaterals to the Left Coronary Artery, and then retrograde into the low-pressure Pulmonary Artery (coronary steal). The hallmark is retrograde flow into the PA.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The question describes a classic presentation of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA). In ALCAPA, the left coronary artery arises from the pulmonary artery instead of the aorta. This leads to a situation where oxygenated blood from the aorta is not directly supplied to the left ventricle. Instead, the left ventricle receives blood from the pulmonary artery, which has lower oxygen saturation.\n\nDuring diastole, the pressure in the pulmonary artery drops significantly. To perfuse the left ventricle, collateral circulation develops from the right coronary artery (which arises from the aorta) to the left coronary artery. However, the primary issue is the origin of the left coronary artery.\n\nThe question asks about the flow pattern that *confirms* the diagnosis of ALCAPA during color Doppler interrogation of the coronary arteries. Let's analyze the options:\n\nA. Diastolic flow from the aorta into the left coronary artery: This would be normal flow if the left coronary artery originated from the aorta. In ALCAPA, the left coronary artery originates from the pulmonary artery.\n\nB. Systolic flow from the pulmonary artery into the left coronary artery: This is the hallmark of ALCAPA. Because the left coronary artery arises from the pulmonary artery, blood will flow from the pulmonary artery into the left coronary artery, especially during systole when pulmonary artery pressure is higher. This is the abnormal origin and the primary flow pattern that confirms the diagnosis.\n\nC. Retrograde flow from the left coronary artery into the pulmonary artery: While collateral flow from the right coronary artery to the left coronary artery can occur, and some of this blood might eventually return to the pulmonary artery, the *confirmatory* finding is the direct flow from the pulmonary artery into the left coronary artery. Retrograde flow is a consequence of the abnormal origin and the attempt to perfuse the myocardium, but not the primary diagnostic flow pattern.\n\nD. Continuous flow from the aorta to the pulmonary artery: This describes a patent ductus arteriosus or an aortopulmonary window, not ALCAPA.\n\nE. Turbulent high-velocity flow at the left coronary ostium: While there might be some turbulence at the origin of the left coronary artery from the pulmonary artery, this is not as specific or confirmatory as the direction of flow. The key is that the flow is originating from the pulmonary artery.\n\nTherefore, the flow pattern that confirms ALCAPA is systolic flow from the pulmonary artery into the left coronary artery.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-007", "question": "A 60-year-old male presents with nephrotic syndrome. Labs show low serum C3 and normal C4. Kidney biopsy reveals C3-dominant staining on immunofluorescence and a membranoproliferative pattern on light microscopy. Serum protein electrophoresis is negative, but serum free light chain assay shows a kappa:lambda ratio of 5.0. What is the most appropriate treatment to preserve renal function?", "options": ["Option A: Eculizumab", "Option B: Mycophenolate Mofetil", "Option C: Clone-directed chemotherapy (e.g., Bortezomib-based)", "Option D: High-dose steroids alone", "Option E: Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "This patient has C3 Glomerulopathy (C3G) secondary to a Monoclonal Gammopathy of Renal Significance (MGRS). The monoclonal protein acts as an autoantibody (e.g., C3 nephritic factor) driving complement activation. The standard of care is to treat the underlying clone (plasma cell directed therapy) rather than non-specific immunosuppression or complement inhibition alone.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with nephrotic syndrome, low C3, normal C4, C3-dominant staining on immunofluorescence, and a membranoproliferative pattern on light microscopy. This constellation of findings, particularly the low C3 and C3-dominant staining, strongly suggests a diagnosis of C3 glomerulopathy. The elevated kappa:lambda ratio in the serum free light chain assay indicates a monoclonal gammopathy, specifically an overproduction of kappa light chains. This monoclonal gammopathy is likely driving the C3 glomerulopathy.\n\nLet's analyze the options:\n\nA. Eculizumab is a complement inhibitor that targets the terminal complement pathway (C5). While it can be effective in atypical hemolytic uremic syndrome (aHUS) and some forms of C3 glomerulopathy with dysregulation of the alternative complement pathway, it's not the primary treatment for C3 glomerulopathy driven by a monoclonal gammopathy.\n\nB. Mycophenolate mofetil is an immunosuppressant. It might be considered in some forms of glomerulonephritis, but it doesn't directly address the underlying monoclonal gammopathy.\n\nC. Clone-directed chemotherapy, such as bortezomib-based regimens, targets plasma cells and B-cells that produce monoclonal proteins. Given the evidence of a monoclonal gammopathy (elevated kappa:lambda ratio) and its likely role in the C3 glomerulopathy, treating the underlying plasma cell dyscrasia is crucial for long-term renal preservation. Bortezomib is a proteasome inhibitor that is effective in treating multiple myeloma and other plasma cell disorders.\n\nD. High-dose steroids alone are often used in nephrotic syndrome, but in C3 glomerulopathy secondary to a monoclonal gammopathy, they are unlikely to be curative and may not address the root cause.\n\nE. Plasma exchange can be used in certain glomerulonephritides, particularly those mediated by circulating immune complexes or antibodies (e.g., anti-GBM disease, lupus nephritis). However, in C3 glomerulopathy driven by a monoclonal gammopathy, it's not the primary or most effective treatment for eliminating the source of the abnormal protein.\n\nConsidering the presence of a monoclonal gammopathy contributing to C3 glomerulopathy, the most appropriate treatment to address the underlying cause and preserve renal function is to target the clone producing the abnormal protein. Therefore, clone-directed chemotherapy is the best option.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-008", "question": "A patient with severe ARDS is ventilated in Assist-Control Volume Control mode. He is deeply sedated but not paralyzed. Ventilator graphics display a time-triggered mandatory breath, followed immediately by a drop in esophageal pressure (diaphragmatic contraction) occurring during the inspiratory phase, which triggers a second breath during exhalation (breath stacking). This phenomenon is best described as:", "options": ["Option A: Double triggering due to flow starvation", "Option B: Reverse triggering", "Option C: Ineffective triggering", "Option D: Premature cycling", "Option E: Auto-triggering"], "answer": "B", "answer_index": 1, "explanation": "Reverse triggering is a form of patient-ventilator dyssynchrony where the passive insufflation from the ventilator mechanically stretches the diaphragm, reflexively inducing a patient respiratory effort (entrainment). If this induced effort is strong enough, it can trigger a second breath (breath stacking). It is distinct from double triggering caused by high patient drive.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The scenario describes a patient on Assist-Control Volume Control (AC-VC) mode. The ventilator delivers a time-triggered mandatory breath. Immediately after this breath starts, the patient's diaphragm contracts (indicated by a drop in esophageal pressure). This patient effort occurs *during* the inspiratory phase of the ventilator's breath. The patient's effort then triggers a *second* breath. The description states this second breath occurs \"during exhalation (breath stacking)\". This implies the patient's effort is so strong and occurs so early in the ventilator's breath that it triggers another breath before the first one has finished its set inspiratory time, leading to breath stacking.\n\nLet's analyze the options:\n\nA. Double triggering due to flow starvation: Double triggering occurs when the patient's inspiratory effort is so strong and sustained that it triggers a second breath from the ventilator *before* the first breath has ended. This is often seen in AC modes when the patient's demand exceeds the set inspiratory flow. The description mentions a second breath being triggered during the inspiratory phase of the first breath, leading to breath stacking. This aligns with double triggering. Flow starvation can contribute to prolonged patient effort, making double triggering more likely.\n\nB. Reverse triggering: Reverse triggering occurs when a ventilator breath triggers spontaneous diaphragmatic activity in the patient. This is the opposite of what is described.\n\nC. Ineffective triggering: Ineffective triggering occurs when the patient makes an inspiratory effort, but the ventilator fails to deliver a breath. This is not what is happening here; the ventilator is delivering a second breath.\n\nD. Premature cycling: Premature cycling occurs when the ventilator ends the inspiratory phase of a breath before the set inspiratory time has elapsed, usually due to patient effort. This is the opposite of breath stacking, where breaths are being added.\n\nE. Auto-triggering: Auto-triggering occurs when the ventilator delivers a breath without any patient effort. This is usually due to leaks in the circuit or excessive sensitivity settings. The scenario clearly states the second breath is triggered by diaphragmatic contraction.\n\nThe key elements are:\n1. A time-triggered mandatory breath.\n2. Patient effort (diaphragmatic contraction) occurring *during* the inspiratory phase of the mandatory breath.\n3. This patient effort triggers a *second* breath.\n4. This leads to breath stacking.\n\nThis sequence of events is characteristic of double triggering, where the patient's strong inspiratory effort during the ventilator's delivered breath causes the ventilator to deliver a second breath. The mention of \"breath stacking\" further supports this, as it's a consequence of double triggering. While flow starvation can be a *cause* of prolonged patient effort leading to double triggering, the phenomenon itself is double triggering.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-009", "question": "A 28-year-old G2P2 woman presents 3 months postpartum with extensive ecchymoses and bleeding from a minor cut. Coagulation studies show aPTT 78s and PT 12s. A mixing study fails to correct the aPTT. Factor VIII activity is <1%. Which agent is the most appropriate first-line therapy for acute bleeding control?", "options": ["Option A: Desmopressin (DDAVP)", "Option B: Cryoprecipitate", "Option C: Recombinant Human Factor VIII", "Option D: Recombinant Porcine Factor VIII", "Option E: High-dose Prednisone"], "answer": "D", "answer_index": 3, "explanation": "This is acquired hemophilia A (postpartum), caused by an inhibitor (autoantibody) to Factor VIII. Human Factor VIII (and Cryoprecipitate) will be neutralized by the inhibitor and is ineffective. First-line hemostatic agents are bypassing agents (rFVIIa or FEIBA) or Recombinant Porcine Factor VIII (which has low cross-reactivity with human anti-FVIII antibodies). Prednisone treats the clone but does not stop acute bleeding.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a prolonged aPTT (78s) and a normal PT (12s), indicating an intrinsic pathway coagulation defect. The mixing study failing to correct the aPTT suggests the presence of an inhibitor. The very low Factor VIII activity (<1%) strongly points to acquired Factor VIII deficiency, likely due to an acquired inhibitor (autoantibody against Factor VIII). This is a serious condition that can lead to severe bleeding.\n\nLet's analyze the options:\n\nA. Desmopressin (DDAVP): DDAVP is effective for mild hemophilia A and von Willebrand disease by stimulating the release of endogenous Factor VIII and von Willebrand factor. However, in the presence of a Factor VIII inhibitor, DDAVP is generally not effective because the body cannot produce sufficient functional Factor VIII to overcome the inhibitor.\n\nB. Cryoprecipitate: Cryoprecipitate is a blood product rich in Factor VIII, fibrinogen, and von Willebrand factor. It can be used to replace Factor VIII in patients with hemophilia A. In the case of an acquired inhibitor, cryoprecipitate can provide a temporary source of Factor VIII, but the inhibitor will neutralize the infused Factor VIII. While it might provide some hemostasis, it's not the most targeted or efficient first-line therapy for acute bleeding control in this scenario, especially with a very low Factor VIII level and a confirmed inhibitor.\n\nC. Recombinant Human Factor VIII: This is a direct replacement of the deficient clotting factor. However, in the presence of an acquired inhibitor, the infused recombinant human Factor VIII will also be neutralized by the autoantibody. Therefore, it is generally not effective as a first-line therapy for acute bleeding control in patients with high-titer inhibitors.\n\nD. Recombinant Porcine Factor VIII: Porcine Factor VIII is antigenically different from human Factor VIII. In some patients with acquired inhibitors to human Factor VIII, there may be cross-reactivity, but often the inhibitor does not neutralize porcine Factor VIII as effectively. Therefore, recombinant porcine Factor VIII can be used as a bypassing agent to achieve hemostasis in patients with inhibitors to human Factor VIII. This is a recognized first-line therapy for acute bleeding in such cases.\n\nE. High-dose Prednisone: Prednisone is an immunosuppressant and is used to treat the underlying autoimmune process that leads to the inhibitor. However, it takes time for prednisone to reduce the inhibitor titer and restore Factor VIII levels. It is not a treatment for acute bleeding control.\n\nConsidering the patient has an acquired inhibitor to Factor VIII and is actively bleeding, the most appropriate first-line therapy for acute bleeding control is an agent that can bypass the inhibitor. Recombinant porcine Factor VIII is designed for this purpose.\n\nThe answer is (D)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-010", "question": "A traveler returns from Malaysian Borneo with daily high-grade fevers and severe thrombocytopenia. Blood smear reveals high parasitemia with 'band form' trophozoites resembling Plasmodium malariae, but the clinical severity mimics Plasmodium falciparum. Which feature distinguishes the replication cycle of this pathogen from P. falciparum?", "options": ["Option A: 24-hour erythrocytic cycle", "Option B: 48-hour erythrocytic cycle", "Option C: 72-hour erythrocytic cycle", "Option D: Presence of a hypnozoite stage", "Option E: Preferential invasion of reticulocytes"], "answer": "A", "answer_index": 0, "explanation": "The pathogen is Plasmodium knowlesi, a zoonotic malaria. A key feature driving its potential for hyperparasitemia and severe disease is its unique 24-hour (quotidian) erythrocytic replication cycle. P. falciparum has a 48-hour cycle, and P. malariae has a 72-hour cycle. P. knowlesi does not have a hypnozoite stage (unlike P. vivax/ovale).", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The question describes a traveler with symptoms suggestive of malaria, specifically high fevers and severe thrombocytopenia, with a blood smear showing high parasitemia and trophozoites resembling *Plasmodium malariae* but with clinical severity mimicking *Plasmodium falciparum*. This clinical presentation strongly suggests *Plasmodium knowlesi*, a species prevalent in Malaysian Borneo that causes a severe, rapidly progressing malaria with a quartan fever pattern (48-hour cycle) but can be as dangerous as falciparum malaria.\n\nLet's analyze the options in the context of *Plasmodium knowlesi*:\n\nA. Option A: 24-hour erythrocytic cycle. This is characteristic of *Plasmodium vivax* and *Plasmodium ovale* (tertian malaria). *P. knowlesi* has a 24-hour cycle in its asexual erythrocytic stage.\n\nB. Option B: 48-hour erythrocytic cycle. This is characteristic of *Plasmodium malariae* (quartan malaria). While the trophozoites can resemble *P. malariae*, the clinical severity and rapid progression are not typical of *P. malariae*.\n\nC. Option C: 72-hour erythrocytic cycle. This is characteristic of *Plasmodium malariae* (quartan malaria). This is incorrect as *P. malariae* has a 48-hour cycle.\n\nD. Option D: Presence of a hypnozoite stage. This is a characteristic feature of *Plasmodium vivax* and *Plasmodium ovale*, which can cause relapsing malaria. *Plasmodium knowlesi* does not have a hypnozoite stage.\n\nE. Option E: Preferential invasion of reticulocytes. This is a characteristic feature of *Plasmodium vivax* and *Plasmodium ovale*. *Plasmodium knowlesi* can infect red blood cells of all ages, but it preferentially infects reticulocytes, leading to high parasitemia.\n\nThe question asks for a feature that *distinguishes* the replication cycle of *this pathogen* (implied to be *P. knowlesi* given the context) from *P. falciparum*. *P. falciparum* has a 48-hour erythrocytic cycle and infects red blood cells of all ages, with a predilection for older cells.\n\nLet's re-evaluate the options considering the distinction from *P. falciparum*:\n\n*   *P. falciparum* has a 48-hour erythrocytic cycle.\n*   *P. falciparum* does not have a hypnozoite stage.\n*   *P. falciparum* does not preferentially invade reticulocytes; it infects all ages of RBCs.\n\nNow, let's consider *P. knowlesi*:\n*   *P. knowlesi* has a 24-hour erythrocytic cycle. This is a key distinguishing feature from *P. falciparum*'s 48-hour cycle.\n*   *P. knowlesi* does not have a hypnozoite stage. This is similar to *P. falciparum*.\n*   *P. knowlesi* preferentially invades reticulocytes. This is different from *P. falciparum*'s broader invasion.\n\nThe question is phrased to highlight a difference in the *replication cycle*. The erythrocytic cycle length is a fundamental aspect of the replication cycle.\n\n*   *P. falciparum* has a 48-hour cycle.\n*   *P. knowlesi* has a 24-hour cycle.\n\nTherefore, the 24-hour erythrocytic cycle of *P. knowlesi* distinguishes it from the 48-hour cycle of *P. falciparum*.\n\nLet's re-examine the options and the question's intent. The question asks what *distinguishes* the replication cycle of *this pathogen* from *P. falciparum*.\n\n*   A. 24-hour erythrocytic cycle: *P. knowlesi* has a 24-hour cycle. *P. falciparum* has a 48-hour cycle. This is a distinguishing feature.\n*   B. 48-hour erythrocytic cycle: This is the cycle of *P. falciparum*. *P. knowlesi* does not have this. So, this is a distinguishing feature, but it's the cycle of *P. falciparum*, not the pathogen in question. The question asks for a feature of *this pathogen* that distinguishes it.\n*   C. 72-hour erythrocytic cycle: Incorrect for both.\n*   D. Presence of a hypnozoite stage: Neither *P. knowlesi* nor *P. falciparum* have a hypnozoite stage. So, this does not distinguish them.\n*   E. Preferential invasion of reticulocytes: *P. knowlesi* preferentially invades reticulocytes. *P. falciparum* infects all ages of RBCs. This is a distinguishing feature.\n\nThe question asks for a feature that distinguishes the *replication cycle*. Both the cycle length and the target cell type are part of the replication cycle. However, the cycle length is a more direct and fundamental aspect of the asexual replication cycle's timing.\n\nGiven the options, the most direct and significant distinguishing feature of the replication cycle of *P. knowlesi* compared to *P. falciparum* is its shorter erythrocytic cycle.\n\nLet's consider the possibility that the question is poorly phrased and might be looking for a feature that *this pathogen* has, which *P. falciparum* lacks, or vice versa, that is a distinguishing feature of their replication cycles.\n\n*   *P. knowlesi* has a 24-hour cycle. *P. falciparum* has a 48-hour cycle. So, the 24-hour cycle is a distinguishing feature of *P. knowlesi*.\n*   *P. knowlesi* preferentially invades reticulocytes. *P. falciparum* infects all ages. So, preferential invasion of reticulocytes is a distinguishing feature of *P. knowlesi*.\n\nHowever, the options are presented as specific cycle lengths or stages. The most prominent and clinically relevant difference in the replication cycle between *P. knowlesi* and *P. falciparum* is the speed of replication, reflected in the erythrocytic cycle length.\n\nThe clinical presentation of daily high-grade fevers is more consistent with a 24-hour cycle (daily fever) or a rapidly progressing 48-hour cycle. *P. knowlesi*'s 24-hour cycle leads to daily fevers, which can be mistaken for *P. falciparum* due to its severity.\n\nLet's re-read the question carefully: \"Which feature distinguishes the replication cycle of this pathogen from P. falciparum?\"\n\n*   *P. knowlesi* has a 24-hour cycle. *P. falciparum* has a 48-hour cycle. Thus, the 24-hour cycle of *P. knowlesi* distinguishes it from *P. falciparum*.\n*   *P. knowlesi* preferentially invades reticulocytes. *P. falciparum* infects all ages. This also distinguishes them.\n\nHowever, option A is \"24-hour erythrocytic cycle\" and option E is \"Preferential invasion of reticulocytes\". Both are valid distinguishing features. We need to pick the *single best* option.\n\nThe question mentions \"daily high-grade fevers\". A 24-hour cycle leads to daily fevers. A 48-hour cycle leads to fevers every other day. The mention of \"daily\" fevers strongly points towards a 24-hour cycle.\n\nTherefore, the 24-hour erythrocytic cycle is the most direct and evident distinguishing feature that aligns with the described clinical presentation.\n\nThe final answer is $\\boxed{A}$."}]